<DOC>
	<DOC>NCT00509769</DOC>
	<brief_summary>This was a multi-institutional, open-label, single-arm, Phase II study of trastuzumab emtansine (T-DM1) administered by intravenous (IV) infusion to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).</brief_summary>
	<brief_title>A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Signed informed consent form. Human epidermal growth factor receptor 2 (HER2)positive metastatic breast cancer (MBC); tissue (slides or blocks) available for HER2 confirmation. History of progression on HER2directed therapy for the treatment of HER2positive breast cancer. At least 1, and no more than 3, chemotherapy regimens for MBC. Granulocyte count ≥ 1500/μL, platelet count ≥ 100,000/μL, and hemoglobin ≥ 9 g/dL. Serum bilirubin ≤ 1.5 mg/dL, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤ 2.5x the upper limit of normal (ULN). Serum creatinine ≤ 1.5 mg/dL or creatinine clearance ≥ 60 mL/min. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. Any chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or biological therapy for the treatment of breast cancer within 2 weeks of the first study treatment. Prior cumulative doxorubicin dose &gt; 360 mg/m^2 or the equivalent. History of significant cardiac disease, unstable angina, congestive heart failure (CHF), myocardial infarction, or ventricular arrythmia requiring medication.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Trastuzumab emtansine</keyword>
	<keyword>MBC</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>HER2-positive breast cancer</keyword>
	<keyword>HER2</keyword>
</DOC>